Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) for Maintenance Treatment in Patients With Platinum-sensitive Relapsed Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer (Collectively Referred to as Ovarian Cancer)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms NORA
- Sponsors ZAI Lab
- 06 Mar 2024 According to a Zai Lab media release, data from this study will be shared in oral presentations at the 2024 Congress of the European Society of Gynaecological Oncology (ESGO) and and the 2024 Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer.
- 14 Oct 2021 Planned End Date changed from 15 Apr 2021 to 24 Aug 2024.
- 08 Jun 2021 Results from subgroup analysis assessing the efficacy of niraparib maintenance therapy with and without secondary cytoreductive surgery (SCS) in platinum-sensitive recurrent ovarian cancer, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.